Collaboration - September 19, 2013
Medivir and Ferrer enter agreement
The two companies have entered an agreement for commercializing a new treatment for agitation associated with schizophrenia and bipolar diseases. The license and distribution agreement concerns commercialization of ADASUVE in the Nordic region. In Europe ADASUVE is approved for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the […]
Drug Development Pharma - September 6, 2013
Medivir discontinues collaboration with Daewoong
The company has announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical. In the collaboration agreement Daewoong has been responsible for the research and development. MIV-210 has a demonstrably competitive antiviral activity but, like other drugs of this class, does not completely eradicate […]